Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicament combination for regrouping human interleukin-11

A human interleukin and drug technology, applied in the direction of drug combination, pharmaceutical formula, peptide/protein composition, etc.

Inactive Publication Date: 2008-04-02
SHANGHAI NEWSUMMIT BIOPHARMA
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report about the direct effect of IL-11 on hepatitis C, and the present invention mainly observes the direct effect of IL-11 on hepatitis C

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0016] The purpose of describing the embodiments of the present invention is to better explain how to implement the present invention. The purpose is only to illustrate, but not to limit the invention in any way.

[0017] 20 observed patients underwent preliminary open-labeled clinical trials of recombinant human interleukin-11. According to clinical diagnostic criteria, the patients were patients with chronic hepatitis C infection and patients with advanced liver disease who had failed anti-HCV therapy.

[0018] Patients who entered the trial were given a dose of 5 μg / kg, administered daily, by subcutaneous injection, for a total of 12 weeks. The primary examination is to conduct pathological biopsy of liver tissue before and after treatment, and compare them according to the Knodell liver histological activity index scoring method. Minor liver changes include plasma alanine aminotransferase (ALT) concentration and platelet count.

[0019] In the test results, the Knodell ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an Aldesleukin-11, which includes the Aldesleukin-11 capable of accepting medicine and salt which can be accepted by the medicine. The invention has the advantages that the Aldesleukin-11 is a human polypeptide recombination gene product which has no heteroimmunization lysogeny and value of curing hepatitis C induced by arterial anoxemia.

Description

technical field [0001] The invention relates to a pharmaceutical combination of recombinant human interleukin-11 (interleukin-11, IL-11), which has a good therapeutic effect on hepatitis C. More specifically, the present invention relates to recombinant human interleukin-11 drug combination and its preparation method. Background technique [0002] Hepatitis C is a prevalent infectious disease worldwide. According to WHO reports, there are about 170 million infected people in the world, with a prevalence rate of about 3%. In my country, the prevalence rate is about 3.2%, and the infected people are about 41 million. Hepatitis C is mainly iatrogenic and non-iatrogenic transmission through blood and blood products, intravenous drug use, sexual transmission, skin and mucous membranes, etc. Acute hepatitis C generally has mild clinical manifestations, is not easy to be recognized by patients and medical staff, and misdiagnosis and missed diagnosis often occur; at the same time,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/20A61P1/16A61P31/14
Inventor 黄阳滨任军严桦
Owner SHANGHAI NEWSUMMIT BIOPHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com